<- Go Home
Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Market Cap
$14.0B
Volume
3.1M
Cash and Equivalents
$1.1B
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$2.2B
Profit Margin
99.04%
52 Week High
$34.31
52 Week Low
$24.05
Dividend
2.64%
Price / Book Value
2.12
Price / Earnings
13.58
Price / Tangible Book Value
2.12
Enterprise Value
$23.6B
Enterprise Value / EBITDA
N/A
Operating Income
$1.9B
Return on Equity
18.00%
Return on Assets
7.04
Cash and Short Term Investments
$1.1B
Debt
$7.6B
Equity
$9.8B
Revenue
$2.3B
Unlevered FCF
-$1.2B
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium